



Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma

Guest Editors:

Prof. Dr. Marco Vivarelli

Hepatobiliary and Abdominal
Transplantation Surgery,
Department of Experimental and
Clinical Medicine, Riuniti
Hospital, Polytechnic University
of Marche, Ancona, Italy

Prof. Dr. Federico Mocchegiani

Hepatobiliary and Abdominal
Transplantation Surgery,
Department of Experimental and
Clinical Medicine, Riuniti
Hospital, Polytechnic University
of Marche, Ancona, Italy

Dr. Andrea Benedetti

Cacciaguerra

Hepatobiliary and Abdominal
Transplantation Surgery,
Department of Experimental and
Clinical Medicine, Riuniti
Hospital, Polytechnic University
of Marche, Ancona, Italy

Deadline for manuscript
submissions:

closed (10 July 2023)



mdpi.com/si/142180

Message from the Guest Editors

Dear Colleagues,

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth highest cause of cancer-related deaths worldwide. Potentially curative treatments, such as surgery, radiofrequency or liver transplantation are available for selected patients only, while transarterial chemoembolization or systemic agents are the best treatments for intermediate and advanced stage disease. Indeed, over the last decade, immunotherapy has transformed the treatment of HCC, in particular, following the introduction of immune checkpoint inhibitors (ICPIs). The identification of prognostic and predictive biomarkers to define the best treatment for each patient is urgent.

The aim of the special issue is to identify, describe or validate prognostic biomarkers for the diagnosis and survival of HCC based. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: gastroenterology, hepatology, hepatobiliary surgery, transplant surgery, interventional and diagnostic radiology, medical oncology.

We look forward to receiving your contributions.



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI